- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Preview: CT vendors crank up low-dose solutions
Protocols that get the most from every x-ray and high-tech algorithms that delete noise will drive CT at this year’s show.
Protocols that get the most from every x-ray and high-tech algorithms that delete noise will drive CT at this year’s show.
GE’s ASIR (adaptive statistical iterative reconstruction) technology will take center stage as a means to reduce patient x-ray dose by up to 50% on the company’s Discovery CT750 HD and LightSpeed VCT. ASIR is now running on more than 450 scanners worldwide, cutting dose for more than 10,000 patients per day, according to the firm. GE competitors will make similar claims for their proprietary versions of iterative reconstruction, Siemens’ IRIS and Philips’ iDOSE.
Toshiba will bring to RSNA 2010 its Adaptive Iterative Dose Reduction (AIDR) for high-end CT dose reductions. The company showcased the product for cardiac CT exams done on its Aquilion One, Aquilion Premium, and all its 64-detector row CT scanners at the European Society of Cardiology Congress in Stockholm, Sweden, in late August. AIDR remains a work-in-progress in the U.S., pending FDA clearance. It will be accompanied by Target CTA, a cardiac protocol for reducing dose on the Aquilion One. The company will also spotlight its work-in-progress 160-detector row spiral scanning technology on the Aquilion One and Aquilion Premium, allowing full chest, abdomen, and pelvis scans in less than five seconds.
GE will port developments in iterative reconstruction for CT to nuclear medicine with the unveiling of its SharpIR, an iterative reconstruction enhancement compatible with the company’s Discovery PET/CT 600 scanners. The CT version, ASIR, will be ported also to PET/CT and SPECT/CT scanners in the GE portfolio to minimize CT dose.
Can MRI-Based AI Bolster Biopsy Decision-Making in PI-RADS 3 Cases?
December 9th 2024In patients with PI-RADS 3 lesion assessments, the combination of AI and prostate-specific antigen density (PSAD) level achieved a 78 percent sensitivity and 93 percent negative predictive value for clinically significant prostate cancer (csPCa), according to research presented at the Radiological Society of North American (RSNA) conference.
The Reading Room: Artificial Intelligence: What RSNA 2020 Offered, and What 2021 Could Bring
December 5th 2020Nina Kottler, M.D., chief medical officer of AI at Radiology Partners, discusses, during RSNA 2020, what new developments the annual meeting provided about these technologies, sessions to access, and what to expect in the coming year.
RSNA 2020: Addressing Healthcare Disparities and Access to Care
December 4th 2020Rich Heller, M.D., with Radiology Partners, and Lucy Spalluto, M.D., with Vanderbilt University School of Medicine, discuss the highlights of their RSNA 2020 session on health disparities, focusing on the underlying factors and challenges radiologists face to providing greater access to care.
New Interventional Radiology Research Shows Merits of Genicular Artery Embolization for Knee OA
December 3rd 2024In a cohort of over 160 patients with knee osteoarthritis (OA), including grade 4 in nearly half of the cases, genicular artery embolization led to an 87 percent improvement in the quality of life index, according to research presented at the
Siemens Healthineers Debuts New Photon-Counting CT Systems at RSNA
December 2nd 2024Debuting at the Radiological Society of North American (RSNA) conference, the new photon-counting computed tomography (PPCT) scanners Naeotom Alpha.Pro and Naeotom Alpha.Prime reportedly combine rapid scan times with high-resolution precision.
